Rheumatology TT

Overarching principles of treating Psoriatic arthritis to target

—

by

Rheumatology TT
in ,
  1. The treatment target must be based on a shared decision between patient and rheumatologist. 
  2. Treatment to target by measuring disease activity, and adjusting therapy accordingly, improves outcomes.
  3. SpA and PsA are multifaceted systemic diseases; the management of musculoskeletal and extra-articular manifestations should be coordinated, as needed, between the rheumatologist and other specialists (such as dermatologists, gastroenterologists, ophthalmologists). 
  4. The goals of treating the patient with axial SpA or PsA are to optimise long-term health-related quality of life and social participation through control of signs and symptoms, prevention of structural damage, normalisation or preservation of function, avoidance of toxicities and minimisation of comorbidities. 
  5. Abrogation of inflammation is important to achieve these goals.
Smolen JS, Schöls M, Braun J, et alTreating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task forceAnnals of the Rheumatic Diseases 2018;77:3-17.

Discover more from Rheumatology TT

Subscribe to get the latest posts sent to your email.